GM1 Gangliosidosis Market Growth To $0.96 Billion By 2030: What’s Driving The Expansion?

GM1 Gangliosidosis Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

GM1 Gangliosidosis Market CAGR Outlook And Future Development

The gm1 gangliosidosis market has seen substantial growth over recent years. Projections indicate its value will increase from $0.57 billion in 2025 to $0.63 billion by 2026, reflecting a compound annual growth rate (CAGR) of 11.1%. Historically, this expansion has been driven by factors such as rare disease research initiatives, the identification of enzyme deficiencies, improvements in genetic diagnostics, hospital-based pediatric care, and initial clinical studies.

The market for gm1 gangliosidosis is projected to experience substantial expansion in the coming years. It is forecast to reach $0.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This growth in the forecast period can be attributed to advancements in the gene therapy pipeline, incentives for orphan drugs, enhanced diagnostic screening, a rise in patient advocacy efforts, and an expansion of biotechnology funding. Major trends anticipated during this period include a heightened focus on rare disease drug development, increased research in gene therapy, a broader application of enzyme replacement therapies, the expansion of newborn genetic screening programs, and increased clinical trial activity.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=26787721&type=smp&name=GM1%20Gangliosidosis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

GM1 Gangliosidosis Market Growth Backed By Core Demand Fundamentals

The rising integration of gene therapy is projected to boost the expansion of the GM1 gangliosidosis market in the future. This therapeutic approach modifies or substitutes genes within human cells to address or avert illnesses. The broader acceptance of gene therapy stems from progress in genetic studies, better results for conditions that were once untreatable, and increasing backing from regulators for new treatments. Specifically for GM1 gangliosidosis, gene therapy entails introducing a working version of the faulty GLB1 gene into patient cells to reactivate ß-galactosidase enzyme and lessen the accumulation of harmful substances. As an example, in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, indicated that the count of gene therapies in Phase III trials experienced a 10% rise in Q4 2023 relative to the prior quarter, marking its initial surge since Q3 2022. Consequently, the expanding use of gene therapy is propelling the growth of the GM1 gangliosidosis market.

GM1 Gangliosidosis Market Segmentation And Category Overview

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

#GM1 Gangliosidosis Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the GM1 gangliosidosis market are concentrating on strategic alliances to preserve their position. These collaborations are essential for fostering gene therapy progress, as they unite expertise, resources, and technologies to accelerate discovery, clinical trials, and market introduction. For example, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, joined forces with Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to advance gene therapies for rare conditions, including GM1 gangliosidosis. This arrangement includes up to $100 million in funding from Fiocruz for clinical investigation and manufacturing, intended to make these cutting-edge therapies available via Brazil’s public healthcare system. The partnership underscores technology transfer and seeks to universalize access to treatments that were historically confined to higher-income demographics.

GM1 Gangliosidosis Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

View The Full GM1 Gangliosidosis Market Report:

https://thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

GM1 Gangliosidosis Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model